A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge

<p>The development of tuberculosis (TB) vaccines has been hindered by the complex nature of <em>Mycobacterium tuberculosis</em> (<em>M.tb</em>) and the absence of clearly defined immune markers of protection. While Bacillus Calmette-Guerin (BCG) is cur...

Full description

Bibliographic Details
Main Authors:	Stylianou, E, Pinpathomrat, N, Sampson, O, Richard, A, Korompis, M, McShane, H
Format:	Journal article
Language:	English
Published:	Frontiers Media 2023

Similar Items

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge
by: Elena Stylianou, et al.
Published: (2023-10-01)

Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
by: Pinpathomrat, N, et al.
Published: (2021)

Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model.
by: Rachel Harrington-Kandt, et al.
Published: (2018-01-01)

Identification and evaluation of novel protective antigens for the development of a candidate TB subunit vaccine
by: Stylianou, E, et al.
Published: (2018)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
by: Riste, M, et al.
Published: (2021)

ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.
by: Truc Hoang, et al.
Published: (2013-01-01)

The ESX-4 substrates, EsxU and EsxT, modulate Mycobacterium abscessus fitness.
by: Marion Lagune, et al.
Published: (2022-08-01)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
by: Michael Riste, et al.
Published: (2021-04-01)

Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen
by: Biffar, L, et al.
Published: (2019)

Priming mycobacterial ESX-secreted protein B to form a channel-like structure
by: Abril Gijsbers, et al.
Published: (2021-01-01)

Prime-boost immunisation strategies for tuberculosis.
by: Mcshane, H, et al.
Published: (2005)

Prime-boost immunization strategies for infectious diseases.
by: Mcshane, H
Published: (2002)

A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance.
by: Alexander eBadamchi-Zadeh, et al.
Published: (2016-04-01)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
by: Mcshane, H
Published: (2008)

Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
by: Chen Xu, et al.
Published: (2018-04-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
by: Raksha Rimal, et al.
Published: (2022-04-01)

Mycobacterium tuberculosis thymidylate kinase antigen assays for designating incipient, high-risk latent M.tb infection
by: Misaki Wayengera, et al.
Published: (2018-03-01)

Mycosins Are Required for the Stabilization of the ESX-1 and ESX-5 Type VII Secretion Membrane Complexes
by: Vincent J. C. van Winden, et al.
Published: (2016-11-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Whelan, K, et al.
Published: (2009)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
by: C.N. Govind, et al.
Published: (2014-04-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
by: Alvarez, MPP, et al.
Published: (2024)

Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M. tb infection model
by: Harrington-Kandt, R, et al.
Published: (2018)

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
by: Sklar, MJ, et al.
Published: (2021)

A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
by: Marvin J Sklar, et al.
Published: (2021-01-01)

The ESX-1 Substrate PPE68 Has a Key Function in ESX-1-Mediated Secretion in Mycobacterium marinum
by: Merel P. M. Damen, et al.
Published: (2022-12-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Kathryn T Whelan, et al.
Published: (2009-06-01)

Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins
by: Zhi-hao Xiang, et al.
Published: (2017-05-01)

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
by: Tchilian, E, et al.
Published: (2009)

Towards new TB vaccines
by: Brazier, B, et al.
Published: (2020)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Erratum: Immunogenicity and protective efficacy of prime-boost regimens with recombinant δureC hly+ Mycobacterium bovis BCG and modified Vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
by: Tchilian, E, et al.
Published: (2011)

In silico EsxG EsxH rational epitope selection: Candidate epitopes for vaccine design against pulmonary tuberculosis
by: Constanza Estefania Martinez-Olivares, et al.
Published: (2023-01-01)

In silico EsxG EsxH rational epitope selection: Candidate epitopes for vaccine design against pulmonary tuberculosis.
by: Constanza Estefania Martinez-Olivares, et al.
Published: (2023-01-01)

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection
by: Matthias I. Gröschel, et al.
Published: (2017-03-01)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
by: Julia L. Hurwitz, et al.
Published: (2010-02-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
by: Giovana Rodrigues Pereira, et al.
Published: (2018-01-01)

The structure of the endogenous ESX-3 secretion system
by: Nicole Poweleit, et al.
Published: (2019-12-01)

The Efficiency of TB LAM Antigen Test to Xpert MTB/RIF Ultra Test for the Diagnosis of Tuberculous Pericarditis Using Pericardial Fluid Samples
by: Samuel Alomatu, et al.
Published: (2023-09-01)